CLINICAL TRIAL: GC1008 IN PATIENTS WITH TREATMENT RESISTANT IDIOPATHIC FSGS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose: To determine in patients with treatment resistant idiopathic FSGS and nephrotic range proteinuria: 1. Safety and tolerability of single dose infusions of GC1008 2. Pharmacokinetics of GC1008 following single dose infusions of GC1008 Participants: Patients with resistant FSGS-5patients in 4 cohorts Procedures (methods): This is a phase I, open-label, and dose-escalation study assessing the safety, tolerability and pharmacokinetic profile of single doses of GC1008 in patients with treatment resistant idiopathic FSGS.